{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T23:37:42Z","timestamp":1773013062575,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R328A19006"],"award-info":[{"award-number":["R328A19006"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007505","name":"Kirsten og Freddy Johansens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,2,8]]},"DOI":"10.1038\/s41416-025-03288-8","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:22:06Z","timestamp":1764786126000},"page":"486-492","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The association between lower urinary tract symptoms and urinary tract infections, and subsequent prostate cancer workup: a nationwide population-based case-control study"],"prefix":"10.1038","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8736-7724","authenticated-orcid":false,"given":"Jeppe Lyngbye","family":"Widding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7293-9506","authenticated-orcid":false,"given":"Hein Vincent","family":"Stroomberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne Oksbjerg","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Brasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"R\u00f8der","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Signe Benzon","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"3288_CR1","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","volume":"360","author":"FH Schr\u00f6der","year":"2025","unstructured":"Schr\u00f6der FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European Study. N Engl J Med. 2025;360:1320\u20138. https:\/\/doi.org\/10.1056\/NEJMoa0810084.","journal-title":"N Engl J Med"},{"key":"3288_CR2","doi-asserted-by":"crossref","unstructured":"James ND, Tannock I, N\u2019Dow J, Feng F, Gillessen S, Ali SA, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403:1683\u2013722.","DOI":"10.1016\/S0140-6736(24)00651-2"},{"key":"3288_CR3","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41585-022-00638-6","volume":"19","author":"H Van Poppel","year":"2022","unstructured":"Van Poppel H, Albreht T, Basu P, Hogenhout R, Collen S, Roobol M. Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future. Nat Rev Urol. 2022;19:562\u201372.","journal-title":"Nat Rev Urol"},{"key":"3288_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/540707","volume":"2013","author":"K Jessen","year":"2013","unstructured":"Jessen K, S\u00f8ndergaard J, Larsen PV, Thomsen JL. Danish general practitioners\u2032 use of prostate-specific antigen in opportunistic screening for prostate cancer: a survey comprising 174 GPs. Int J Fam Med. 2013;2013:540707. https:\/\/doi.org\/10.1155\/2013\/540707.","journal-title":"Int J Fam Med"},{"key":"3288_CR5","unstructured":"Dansk Selskab for Almen Medicin (DSAM). Klinisk vejledning for almen praksis: udredning og behandling af nedre urinvejssymptomer hos m\u00e6nd og kvinder. 2009. https:\/\/www.dsam.dk\/vejledninger\/urinvejssymptomer\/prostata-specifi-kt-antigen-psa-hvad-kan-psa-bruges-til."},{"key":"3288_CR6","doi-asserted-by":"publisher","first-page":"k1202","DOI":"10.1136\/bmj.k1202","volume":"361","author":"J \u00d8ster\u00f8 \u00cd J\u00e1kupsstovu","year":"2018","unstructured":"\u00d8ster\u00f8 \u00cd J\u00e1kupsstovu J, Brodersen J. Do men with lower urinary tract symptoms have an increased risk of advanced prostate cancer?. BMJ. 2018;361:k1202.","journal-title":"BMJ"},{"key":"3288_CR7","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3399\/bjgp18X699689","volume":"68","author":"J Just","year":"2018","unstructured":"Just J, Osgun F, Knight C. Lower urinary tract symptoms and prostate cancer: is PSA testing in men with symptoms wise?. Br J Gen Pr. 2018;68:541\u20132.","journal-title":"Br J Gen Pr"},{"key":"3288_CR8","doi-asserted-by":"publisher","unstructured":"Raychaudhuri R, Lin DW, Montgomery RB. Prostate cancer: a review. JAMA. 2025. https:\/\/doi.org\/10.1001\/jama.2025.0228.","DOI":"10.1001\/jama.2025.0228"},{"key":"3288_CR9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806\u20138.","journal-title":"BMJ"},{"key":"3288_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s10916-023-01991-8","volume":"47","author":"HV Stroomberg","year":"2023","unstructured":"Stroomberg HV, Larsen SB, Lanth\u00e9n GS, Nielsen TK, Helgstrand JT, Brasso K, et al. Danish Prostate Registry (DanProst) \u2013 an updated version of the danish prostate cancer registry, methodology, and early results. J Med Syst. 2023;47:98 https:\/\/doi.org\/10.1007\/s10916-023-01991-8.","journal-title":"J Med Syst"},{"key":"3288_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/1403494811401482","volume":"39","author":"E Lynge","year":"2011","unstructured":"Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39:30\u20133.","journal-title":"Scand J Public Health"},{"key":"3288_CR12","first-page":"798","volume":"46","author":"A Potteg\u00e5rd","year":"2017","unstructured":"Potteg\u00e5rd A, Schmidt SAJ, Wallach-Kildemoes H, S\u00f8rensen HT, Hallas J, Schmidt M. Data resource profile: The Danish National Prescription Registry. Int J Epidemiol. 2017;46:798\u2013798f.","journal-title":"Int J Epidemiol"},{"key":"3288_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/1403494810393562","volume":"39","author":"ML Gjerstorff","year":"2011","unstructured":"Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health. 2011;39:42\u20135.","journal-title":"Scand J Public Health"},{"key":"3288_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"3288_CR15","unstructured":"DAPROCA. Opsporing og diagnostisk udredning af prostatacancer. 2024. https:\/\/www.dmcg.dk\/siteassets\/kliniske-retningslinjer---skabeloner-og-vejledninger\/kliniske-retningslinjer-opdelt-pa-dmcg\/daproca\/daproca_opspor_diagnos_udred_prosta_v2.0_admgodk_12112024.pdf."},{"key":"3288_CR16","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2021. https:\/\/www.r-project.org\/."},{"key":"3288_CR17","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.eururo.2012.12.060","volume":"63","author":"CJ Weight","year":"2013","unstructured":"Weight CJ, Kim SP, Jacobson DJ, McGree ME, Boorjian SA, Thompson RH, et al. The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis. Eur Urol. 2013;63:1021\u20137.","journal-title":"Eur Urol"},{"key":"3288_CR18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/21681805.2018.1444672","volume":"52","author":"N Klemann","year":"2018","unstructured":"Klemann N, R\u00f8der MA, Helgstrand JT, Brasso K, Toft BG, Vainer B, et al. The use of transrectal ultrasound-guided biopsy following the introduction of prostate-specific antigen testing in Denmark: a population-based analysis. Scand J Urol. 2018;52:169\u201373. https:\/\/doi.org\/10.1080\/21681805.2018.1444672.","journal-title":"Scand J Urol"},{"key":"3288_CR19","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1002\/ijc.23713","volume":"123","author":"RM Martin","year":"2008","unstructured":"Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TIL. Lower urinary tract symptoms and risk of prostate cancer: the HUNT 2 Cohort, Norway. Int J Cancer. 2008;123:1924\u20138.","journal-title":"Int J Cancer"},{"key":"3288_CR20","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.3109\/0284186X.2013.831474","volume":"52","author":"RV Karlsen","year":"2013","unstructured":"Karlsen RV, Larsen SB, Christensen J, Brasso K, Friis S, Tj\u00f8nneland A, et al. PSA testing without clinical indication for prostate cancer in relation to socio-demographic and clinical characteristics in the Danish Diet, Cancer and Health Study. Acta Oncol. 2013;52:1609\u201314.","journal-title":"Acta Oncol"},{"key":"3288_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1464-410X.2008.08306.x","volume":"104","author":"M Borre","year":"2009","unstructured":"Borre M. Screening by lower urinary tract symptoms vs asymptomatic prostate-specific antigen levels leading to radical prostatectomy in Danish men: tumour characteristics and treatment outcome. BJU Int. 2009;104:205\u20138.","journal-title":"BJU Int"},{"key":"3288_CR22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 update on prostate cancer epidemiology and risk factors\u2014a systematic review. Eur Urol. 2023;84:191\u2013206. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.021.","journal-title":"Eur Urol"},{"key":"3288_CR23","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/j.1464-410X.2008.07817.x","volume":"102","author":"SM Collin","year":"2008","unstructured":"Collin SM, Metcalfe C, Donovan J, Lane JA, Davis M, Neal D, et al. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment). BJU Int. 2008;102:1400\u20136.","journal-title":"BJU Int"},{"key":"3288_CR24","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/j.1464-410X.2012.10962.x","volume":"110","author":"M Fr\u00e5nlund","year":"2012","unstructured":"Fr\u00e5nlund M, Carlsson S, Stranne J, Aus G, Hugosson J. The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of \u22653.0 ng\/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial. BJU Int. 2012;110:638\u201343.","journal-title":"BJU Int"},{"key":"3288_CR25","doi-asserted-by":"publisher","first-page":"n2305","DOI":"10.1136\/bmj.n2305","volume":"375","author":"MB Bengtsen","year":"2021","unstructured":"Bengtsen MB, Farkas DK, Borre M, S\u00f8rensen HT, N\u00f8rgaard M. Acute urinary retention and risk of cancer: population based Danish cohort study. BMJ. 2021;375:n2305.","journal-title":"BMJ"},{"key":"3288_CR26","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.eururo.2011.06.016","volume":"60","author":"DD \u00d8rsted","year":"2011","unstructured":"\u00d8rsted DD, Bojesen SE, Nielsen SF, Nordestgaard BG. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men. Eur Urol. 2011;60:691\u20138.","journal-title":"Eur Urol"},{"key":"3288_CR27","first-page":"756","volume":"56","author":"W Hamilton","year":"2006","unstructured":"Hamilton W, Sharp DJ, Peters TJ, Round AP. Clinical features of prostate cancer before diagnosis: a population-based, case-control study. Br J Gen Pr. 2006;56:756\u201362.","journal-title":"Br J Gen Pr"},{"key":"3288_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.eururo.2022.01.018","volume":"82","author":"RA Godtman","year":"2022","unstructured":"Godtman RA, Kollberg KS, Pihl CG, M\u00e5nsson M, Hugosson J. The association between age, prostate cancer risk, and higher Gleason score in a long-term screening program: results from the G\u00f6teborg-1 prostate cancer screening trial. Eur Urol. 2022;82:311\u20137.","journal-title":"Eur Urol"},{"key":"3288_CR29","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","volume":"29","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Pedersen L, S\u00f8rensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29:541\u20139.","journal-title":"Eur J Epidemiol"},{"key":"3288_CR30","unstructured":"CDC: Centers for Disease Control and Prevention. Diagnosing prostate cancer. 2024. https:\/\/www.cdc.gov\/prostate-cancer\/diagnosis\/index.html."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03288-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03288-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03288-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T15:55:15Z","timestamp":1769615715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03288-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,8]]}},"alternative-id":["3288"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03288-8","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HVS has received travel expenses and speaking and lecture fees from MSD Denmark, and project support from Pfizer Denmark outside of the scope of this manuscript. KB has received speaker fees from Bayer Denmark outside the scope of this manuscript. AR has received project support from Bayer Denmark and Pfizer Denmark, prior speaker fee from Astellas Nordic, and advisory and consultancy for Pfizer, Amgen, MSD, Sanofi, Janssen, Astra-Zeneca, Recordati, Astellas, Bayer, Orion, Ferrin, Medtronic, and Intuitive outside of the scope of this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The present study was performed in accordance with the Declaration of Helsinki. It was based on anonymized, centrally located Danish national register data, and approvals by relevant authorities have been obtained: Usage of DanProst by Danish Patient Safety Authority (Journal-nr.: 31-1521-330), creation and approval of the project at Statistic Denmark (Project nr.: 708122), and Danish Health Data Authority (Prescription Registry) (FEID-00005346).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}